Javascript must be enabled to continue!
Abstract LB-80: Building Bridges for Pancreatic Cancer Research
View through CrossRef
Abstract
Almost 40 years after President Nixon signed into law the National Cancer Act, the survival rate for pancreatic cancer has not substantially improved. Today, 75 percent of patients diagnosed with pancreatic cancer die within one year of diagnosis, and 94 percent of pancreatic cancer patients will die within five years of diagnosis.
Although pancreatic cancer is the fourth leading cause of cancer death in the U.S., causing 36,800 deaths in 2010, only two percent of the National Cancer Institute's budget is spent on researching the disease ($89.4 million in 2009). Early detection tools for pancreatic cancer do not exist, and thus, patients are typically diagnosed after the disease has metastasized and surgery is no longer a possibility.
Jason Peckenpaugh became an independent advocate for pancreatic cancer patients and research after seeing his father, Jon, bravely battle pancreatic cancer for 18 months until his passing in October 2009. Mr. Peckenpaugh's fight illustrates the statistics above, including his seven month quest to simply discover his diagnosis.
The focus of his advocacy work is communicating scientific information with caregivers, patients, and the public, while sharing the perspective of patients and caregivers with oncologists and researchers. He is participating in the AACR Scientist<–>Survivor Program to improve my knowledge of cancer science and research so that he may become a patient advocate on GI cancer grant committees and/or research control boards. Despite the poor prognosis for patients with pancreatic cancer, this is a promising time for pancreatic cancer research, in part due to grants from the Stand Up 2 Cancer organization, advances in molecular profiling of tumors, and recent research showing the progression of pancreatic cancer. Pancreatic cancer needs a patient advocate at the table wherever gastrointestinal cancers and other cancers are being discussed. Patient advocates serve on grant review boards of the Food and Drug Administration, the Gastrointestinal Specialized Program of Research Excellence (GI SPORE), and other government research consortia.
Mr. Peckenpaugh is a volunteer with the Pancreatic Cancer Action Network (PanCAN) and a volunteer fundraiser for the Lustgarten Foundation and Johns Hopkins University's pancreatic cancer research program. He has raised more than $14,000 for pancreatic cancer research since 2008.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-80. doi:10.1158/1538-7445.AM2011-LB-80
Title: Abstract LB-80: Building Bridges for Pancreatic Cancer Research
Description:
Abstract
Almost 40 years after President Nixon signed into law the National Cancer Act, the survival rate for pancreatic cancer has not substantially improved.
Today, 75 percent of patients diagnosed with pancreatic cancer die within one year of diagnosis, and 94 percent of pancreatic cancer patients will die within five years of diagnosis.
Although pancreatic cancer is the fourth leading cause of cancer death in the U.
S.
, causing 36,800 deaths in 2010, only two percent of the National Cancer Institute's budget is spent on researching the disease ($89.
4 million in 2009).
Early detection tools for pancreatic cancer do not exist, and thus, patients are typically diagnosed after the disease has metastasized and surgery is no longer a possibility.
Jason Peckenpaugh became an independent advocate for pancreatic cancer patients and research after seeing his father, Jon, bravely battle pancreatic cancer for 18 months until his passing in October 2009.
Mr.
Peckenpaugh's fight illustrates the statistics above, including his seven month quest to simply discover his diagnosis.
The focus of his advocacy work is communicating scientific information with caregivers, patients, and the public, while sharing the perspective of patients and caregivers with oncologists and researchers.
He is participating in the AACR Scientist<–>Survivor Program to improve my knowledge of cancer science and research so that he may become a patient advocate on GI cancer grant committees and/or research control boards.
Despite the poor prognosis for patients with pancreatic cancer, this is a promising time for pancreatic cancer research, in part due to grants from the Stand Up 2 Cancer organization, advances in molecular profiling of tumors, and recent research showing the progression of pancreatic cancer.
Pancreatic cancer needs a patient advocate at the table wherever gastrointestinal cancers and other cancers are being discussed.
Patient advocates serve on grant review boards of the Food and Drug Administration, the Gastrointestinal Specialized Program of Research Excellence (GI SPORE), and other government research consortia.
Mr.
Peckenpaugh is a volunteer with the Pancreatic Cancer Action Network (PanCAN) and a volunteer fundraiser for the Lustgarten Foundation and Johns Hopkins University's pancreatic cancer research program.
He has raised more than $14,000 for pancreatic cancer research since 2008.
Citation Format: {Authors}.
{Abstract title} [abstract].
In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL.
Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-80.
doi:10.
1158/1538-7445.
AM2011-LB-80.
Related Results
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract
Pancreatic adenocarcinoma (PDAC) remains one of the most lethal cancers today and is expected to be the second cause of cancer death in the coming decade. M...
Abstract 1695: Imaging of the interaction of pancreatic cancer and stellate cells during liver metastasis
Abstract 1695: Imaging of the interaction of pancreatic cancer and stellate cells during liver metastasis
Abstract
Pancreatic stellate cells are involved in fibrosis of pancreatic cancer. An understanding of pancreatic cancer-cell interactions with stellate cells is crit...
Abstract 1603: Intra-pancreatic fat promotes the progression of PDAC by activating thermogenesis
Abstract 1603: Intra-pancreatic fat promotes the progression of PDAC by activating thermogenesis
Abstract
Background: The presence of minimal intra-pancreatic fat deposition (IPFD) in the healthy human pancreas has been demonstrated in numerous studies. But exce...
Potential regulatory mechanisms of hsa_circ_0131457/miR-636/SFRP2 inhibition of tumor progression in pancreatic ductus adenocarcinoma
Potential regulatory mechanisms of hsa_circ_0131457/miR-636/SFRP2 inhibition of tumor progression in pancreatic ductus adenocarcinoma
Abstract
Background: Circular RNAs (circRNAs), a novel class of non-coding RNAs, have been found to act as miRNA sponges that competitively inhibit the binding of miRNA to ...
High KLK7 Expression Predicts Unfavorable Outcomes in Patients with Resectable Pancreatic Ductal Adenocarcinoma
High KLK7 Expression Predicts Unfavorable Outcomes in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Abstract
Background Studies have shown that kallikrein-related peptidase 7 (KLK7) is abnormally expressed in a various of tumours and plays a crucial role in tumour progres...
Abstract 3516: Tetrandrine promotes pancreatic cancer cell apoptosis in vitro and tumor regression in vivo
Abstract 3516: Tetrandrine promotes pancreatic cancer cell apoptosis in vitro and tumor regression in vivo
Abstract
Introduction: Resistance to apoptosis is a hallmark of tumor progression and therapeutic failure in cancer, including Pancreatic Cancer. Pancreatic ductal a...
Abstract A044: Persistence of fetal splanchnic gene signature defines a tumor-restraining fibroblast subtype in pancreatic cancer
Abstract A044: Persistence of fetal splanchnic gene signature defines a tumor-restraining fibroblast subtype in pancreatic cancer
Abstract
The pancreas is composed of the epithelial and mesenchymal cells. While mesenchymal fibroblasts are a minor component of the normal pancreas, fibroblast pop...
The Dual Effects of Silibinin on Human Pancreatic Cells
The Dual Effects of Silibinin on Human Pancreatic Cells
Objective: Silibinin is a flavonoid with antihepatotoxic properties, and exhibits pleiotropic anticancer effects. However, the molecular mechanisms responsible for its anticancer a...

